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SulTlmary 
Elevation of cAMP can cause gene-specific inhibition ofinterleukin 2 (IL-2) expression. To investigate 
the mechanism of this effect, we have combined electrophoretic mobility shift assays and in vivo 
genomic footprinting to assess both the availability of putative IL-2 transcription factors in forskolin- 
treated cells and the functional capacity of these factors to engage their sites in vivo. All observed 
effects of forskolin depended upon protein kinase A, for they were blocked by introduction of 
a dominant negative mutant subunit of protein kinase A. In the EL4.E1 cell line, we report 
specific inhibitory effects of cAMP elevation both on NF-KB/Rel family factors binding at -200 
bp, and on a novel, biochemically distinct "TGGGC" factor binding at -225 bp with respect 
to the IL-2 transcriptional start site. Neither NF-AT nor AP-1 binding activities are detectably 
inhibited in gel mobility shift assays. Elevation of cAMP inhibits NF-KB activity with delayed 
kinetics in association with a delayed inhibition of IL-2 kNA accumulation. Activation of cells 
in the presence of forskolin prevents the maintenance ofstable protein-DNA interactions in vivo, 
not only at the NF-KB and TGGGC sites of the IL-2 enhancer, but also at the NF-AT, AP-1, 
and other sites. This result, and similar results in cyclosporin A-treated cells, imply that individual 
IL-2 transcription factors cannot stably bind their target sequences in vivo without coengagement 
of all other distinct factors at neighboring sites. It is proposed that nonhierarchical, cooperative 
enhancement of binding is a structural basis of combinatorial transcription factor action at the 
ILo2 locus. 
A•ct ivat ion  of T helper cells results in secretion of diverse lymphokines. The precise combinationof lymphokines 
produced is variable, depending on the circumstances of the 
activation process. Different effector mechanisms are triggered 
by different lymphokines. Locally and systemically, the rela- 
tive levels of different lymphokines with respect o one an- 
other strongly affect in vivo outcomes. Thus, the type of im- 
mune response that is mobilized ultimately depends on the 
differential transcriptional regulation of lymphokine genes. 
The major stimulatory signal for lymphokine production is 
delivered by engagement of the TCR with antigen in the 
context of MHC on APCs. However, engagement of acces- 
sory molecules on the T cell with additional ligands, either 
on APCs or in the microenvironment, may also deliver other 
kinds of signals that affect lymphokine gene expression 
differentially. Expression of the T cell growth factor, IL-2, 
is particularly susceptible to this kind of modulation. Glucocor- 
ticoids inhibit IL-2 induction preferentially (1-3), and con- 
tact of a T cell with antigen in the absence of a CD28 ligand 
can drive the T cell into an anergic state in which IFN-y 
can be expressed, but not IL-2 (4, 5). Agonists that elevate 
cAMP levels, such as prostaglandin E1 and E2, give especially 
clear evidence for selective inhibition of IL-2 expression (6, 
7), as they can inhibit IL-2 expression in cases where there 
is no inhibition of IL-4 expression at all (8-10). The effects 
of cAMP on T cells can be exerted at both cell- and gene- 
specific levels, depending on the cells and stimuli used. In 
certain IL-2-producing cells, cAMP elevation can uncouple 
the TCR/CD3 complex from its downstream signaling medi- 
ators, preventing the generation of Ca 2§ and protein kinase 
C signals (11-13). On the other hand, even when Ca z+ and 
protein kinase C signals are provided pharmacologically, cAMP 
elevation can still interfere selectively with induction of IL-2 
gene expression, yet allowing other responses to proceed. It 
is the mechanism of this second, gene-specific effect hat we 
investigate here. 
The IL-2 gene regulatory region consists of compact, 
clustered binding sites for an assortment oftranscription factors 
that are disparately regulated (14). In most or all cases tudied, 
IL-2 expression is induced only when all the known factors 
are present, and the ILo2 promoter only works at maximal 
ef~ciency when all the major binding sites for these factors 
are intact. However, in physiological situations, data seem 
to indicate that certain factors play more critical roles than 
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others. Two of them, AP-1 and NF-AT, appear epeatedly 
to be rate limiting for IL-2 expression. When selective down- 
regulation of IL-2 production is caused by exposing T cells 
to glucocorticoids, the possible mechanisms are a protein-pro- 
tein interaction that sequesters AP-1 by dimerization of AP-1 
components with the glucocorticoid receptor (2), or a specific 
inhibition of interaction between AP-1 and NF-AT (3). When 
IL-2-producing cells have been anergized and become un- 
able to express IL-2, their failure appears to be due to either 
a general block of NF-AT, NF-KB, and AP-1 activation (15), 
or a selective inability to activate AP-1 (16). The potent 
immune-suppressive drugs cyclosporin A (CsA) 1 and FK 506 
completely block IL-2 transcription by blocking the nuclear 
translocation of one component of NF-AT (17). Whereas this 
is an example of strictly pharmacological inhibition, defects 
in both NF-AT and AP-I mobilization also appear to be 
responsible for a normal developmental block in the ability 
to express IL-2, namely in cortical thymocytes (18). A similar 
phenotype is observed in a pre-mast cell line that can express 
IL-4 but not IL-2 (19). Thus, an important question is whether 
all physiological regulation of IL-2 expression is exerted 
through effects on AP-1 or NF-AT, or whether cAMP- 
elevating agonists might inhibit IL-2 expression through effects 
on different factors. 
To address these questions, we have chosen EL4.E1 thy- 
moma cells as a model T cell system, and the Ca 2+ iono- 
phore A23187 and the phorbol ester PMA (TPA) as stimulants 
that can bypass any effects of cAMP on signal generation at 
the cell membrane. Using this system previously, we showed 
that cAMP could inhibit IL-2 transcription (9). We also ob- 
tained initial indications that elevation of cAMP caused aslight 
decrease in the binding activity of NF-xB, but did not in- 
hibit NF-AT or AP-1 site binding activities (20). In our present 
studies, we have clearly defined two specific effects of cAMP 
on factor-binding activities and examined the resulting pro- 
tein-DNA interactions at the IL-2 locus in vivo. Our results 
confirm that cAMP, acting via activation of protein kinase 
A (PKA), selectively affects the in vitro DNA binding ac- 
tivities of NF-KB and a newly described TGGGC binding 
factor, and that it does so with novel and distinctively delayed 
kinetics. No evidence was found for any negative ffect on 
NF-AT or AP-1 binding. However, cells stimulated in the 
presence of forskolin failed to sustain stable protein-DNA con- 
tacts at a broad array of sites spanning the entire IL-2 en- 
hancer region. The lack of occupancy may be evidence for 
a new role for NF-xB and TGGGC binding activities, as re- 
quired partners in transcription complex assembly. 
Materials and Methods 
Cells. EL4.E1 cells (EL4) were grown in RPMI-1640 in the 
presence of 2 mM L-glutamine, 50 mM 13-ME, antibiotics, and 6% 
1 Abbreviations used in this paper: CsA, cyclosporin A; DMS, dimethyl 
sulfate; EMSA, electrophoretic mobility shift assay; PKA, protein kinase 
A; TPA, 12-O-tetradecanoyl phorbol 13-acetate (PMA). 
fetal bovine serum (Hyclone, Logan, UT). Cells were cultured to 
confluence before stimulation and were stimulated at 1-2 x 106 
cells/ml using 17 nM TPA and 120 nM A23187 in the presence 
or absence of 10/~M of forskolin (Sigma Chemical Co., St. Louis, 
MO), which raises the cAMP level by directly activating adenylate 
cyclase. Recombinant human IL-la (Genzyme Corp., Cambridge, 
MA) was used at 50 U/ml. 
11,2 Analysis. RNase probe protection analysis to quantitate 
IL-2 RNA was performed as previously described (19, 21). For each 
sample, 10/xg of RNA was used to hybridize with the 11,-2 probe 
(22), and 1/~g RNA was used to hybridize with either an actin 
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe (23). 
Cyclic AMPAssay. Levels of cAMP were measured in EL4 cells 
as described previously using an Amersham dual-range cAMP kit 
(9), except hat nonacetylated standards and samples were used. 
Gel Mobility shift Assays. Nuclear extracts of EL4 cells were 
prepared as before (18). Double-stranded oligonucleotide corre- 
sponding to portions of the mouse IL-2 gene regulatory egion were 
labeled by end filling with c~-[32p]deoxynucleoside triphosphates. 
The detailed sequences and corresponding sites relative to the tran- 
scription start site were described elsewhere (18-20). Oligonucleo- 
tides used for this experiment were synthesized in the California 
Institute of Technology Biology Microchemical Facility. The binding 
reaction and gel electrophoresis procedures were exactly as reported 
before (18). Note that these conditions for detection of NF-AT site 
binding activity differ from those we used in initial studies (20), 
as poly (dI-dC) is used as a nonspecific ompetitor in place of poly 
(dA-dT). In our hands, this substitution yields a spectrum of gel- 
shift complexes more consistent with NF-AT complexes described 
elsewhere, and less dominated by highly protease-sensitive com- 
plexes. However, the insensitivity of NF-AT site binding factors 
to forskolin reported in our earlier study (20) is confirmed here. 
In vivo Footprinting Analysis. The genomic footprinting anal- 
ysis was done as before with the same set of IL-2 gene primers pre- 
viously reported (19). Briefly, 3 x 107 cells were concentrated into 
1 ml medium, and treated with 0.1% of dimethylsulfate at 37~ 
for 1 rain. The reaction was stopped by transferring the cells to 
a tube containing 49 ml of ice-cold PBS, and the cells were pelleted 
and washed once more with 50 ml PBS. The cell pellet was then 
resuspended in 3 ml of lysis buffer (300 mM NaC1, 50 mM Tris, 
pH 8.0, 25 mM EDTA, pH 8.0, 200/xg/ml proteinase K, and 0.2% 
SDS), and incubated at 37~ overnight. Nucleic acids were obtained 
by phenol/chloroform extraction and isopropanol precipitation, then 
subjected to piperidine cleavage and subsequent ligation-mediated 
PCR (24). The final labeled PCR products were separated on a 
6% polyacrylamide s quencing gel. 
Transfection and Selection. 10 #g of linearized HL-REV~pKOneo 
(designated pAPKA in the text) (a gift from G. S. McKnight, 
University of Washington, Seattle, WA) was electroporated at 960 
#F and 320 V into 107 EL4.E1 cells in 1 ml of serum-free RPMI- 
1640 medium with supplements and 14.4 mM H-ME. The cells 
were then diluted into 50 ml of medium and plated in two 24-well 
plates (1 ml/well). 2 d after plating, G418 (GIBCO BRL, Gaithers- 
burg, MD) was added to the wells at 400 #g/ml. Positive wells 
were identified 7-10 d after selection and the cells were expanded 
in 200/xg/ml G418 for further analysis. The plasmid DNAs, pBR322 
and pSV2neo (25), were used in transfection asnegative and posi- 
tive controls. Integration of the mutant PKA construct in estab- 
lished transfectant lines was confirmed by Southern blot analysis 
and its expression was further confirmed by Northern blot anal- 
ysis. One mutant PKA transfectant line, IIA4, and two pSV2neo 
control ines were used in the subsequent experiments. 
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Results 
Forsteolin Affects DNA-binding Activities of a Specific Subset 
of Factors. To investigate the effects of cAMP on IL-2 tran- 
scriptional control, EL4 cells were stimulated with TPA+ 
A23187 in the presence or absence of 10/zM of forskolin, 
and the IL-2 mRNA level in the cells was examined 5 h after 
induction (Fig. 1 A). Addition of forskolin to the 
TPA+A23187 stimuli significantly decreased the level of IL-2 
mRNA (Fig. 1 A, lane 3). In previous work (9), we reported 
that forskolin could also inhibit inducible expression of a 
reporter gene under the control of the minimal 321-bp IL-2 
promoter/enhancer. This indicated that at least part of the 
effect of forskolin was mediated through the 5' regulatory 
sequence of the IL-2 gene, presumably at the level of tran- 
scriptional initiation, and that the "~300 bp minimal pro- 
moter/enhancer sequence was sufficient to produce this re- 
sponse. Therefore, to determine the mechanism of the forskolin 
inhibition effect, we focused on protein-DNA interactions 
in this 300-bp region. 
To ascertain whether forskolin inhibits the binding of par- 
ticular factors to the IL-2 regulatory region, we compared 
the levels of most DNA binding activities known to be cor- 
related with IL-2 gene activation in nuclear extracts from 
stimulated cells and from cells stimulated in the presence of 
forskolin. Nuclear extracts were prepared from EL4 cells in- 
cubated under different conditions for 4-5 h, and these ex- 
tracts were analyzed for sequence-specific binding activities 
by electrophoretic mobility shift assays (EMSAs) (Fig. 1, B 
and C). Double stranded oligonucleotide probes were chosen 
to span all the major sites of protein-DNA contact in IL- 
2-producing EL4 cells, as previously identified by in vivo foot- 
printing (19). As shown in Fig. 1 C, the DNA binding ac- 
tivities of factors that are constitutively present, such as the 
Figure 1. II.-2 expression a d nuclear DNA-binding activities in EL4 
cells after stimulation in the presence or abs nce of forskolin. (A) RNase 
protection analysis of IL-2 RNA expression. Total cytoplasmic RNA (10 
#g) from unstimulated cells (lane 1), from cells stimulated for 5 h (lane 
2) with TPA+A23187, or from cells stimulated for 5 h with TPA+A23187 
in the presence of forskolin (lane 3), or 30 #g of yeast RNA (lane 4) 
were hybridized with IL-2 probe or a control GAPDH probe and quanti- 
tated by ribonuclease protection assay. (B) EMSAs of NF-KB and TGGGC 
DNAobinding activities. Corresponding nuclear extracts from the same 
populations of EL4 cells used in A were tested for NF-KB (lanes I-3) and 
TGGGC (lanes 4-6) site binding activities. (C) EMSAs of other factors. 
Nuclear extracts corresponding to the same t ree populations (unstimu- 
lated, lanes 1, 4, 7, I0, 13, and 16; stimulated, lanes 2, 5, 8, 1I, 14, and 
17; and stimulated for 5 h in the presence of forskolin for 5 h, lanes 3, 
6, 9, 12, 15, and 17) were compared for binding activities o th  distal 
NF-ATd site (lanes I-3), the proximal NF-ATp site (lanes 4-6), the AP-1 
site (7-9), the distal CACCCd site (lan s I0-12), the proximal CACCCp 
site (lanes 13-15), and proximal octamer (16-18) sites. Large arrowheads 
in B and C indicate the major complexes at each site. At the Oct site, 
the complexes arelikely to represent Oct-l, Oct-2B, and Oct-2A. Minor 
complexes at the CACCC site (small arrowheads) are discussed in the text. 
(-) Unstimulated; (+) stimulated; and (F) stimulated in the presence of 
forskolin. 
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major binding factors for the CACCC sites (18, 19), and the 
proximal octamer site, were not affected by forskolin (Fig. 
1 C, lanes 10-18, large arrowheads). Similarly, some induction- 
dependent activities, such as the major inducible complexes 
binding the NF-AT and AP-1 sites, were unaffected or even 
slightly enhanced by stimulation i  the presence of forskolin 
(Fig. 1 C, lanes 1-9, large arrowheads). These results are in 
agreement with our previous conclusions from more limited 
studies (20). However, as shown in Fig. 1 B, binding activi- 
ties of several other inducible factors were significantly re- 
duced in nuclear extracts from cells that were activated in 
the presence of forskolin. Most prominent among these were 
the upper complexes binding to the NF-KB and TGGGC sites 
(Fig. 1 B, lanes 2, 3 and 5, 6). In addition, we noted effects 
of forskolin on minor complexes binding the two CACCC 
sites, which in both cases were of faster mobility than the 
major CACCC complex (Fig. 1 C, lanes 11, i2, and 14, 15, 
small arrowheads). The identities of the lower inducible com- 
plexes bound to the CACCC sites are not known. They could 
not be competed by a consensus Sp-1 oligonucleotide as could 
the major CACCC binding complexes (18, and data not 
shown). The nature of the TGGGC binding factor is also 
not known. As it appeared to show a similar electrophoretic 
mobility to that of the upper NF-KB complex, it was sub- 
jected to some further characterization. 
Although both NF-KB and TGGGC binding activities were 
coinhibited by forskolin, the protein components involved 
were clearly different. This was confirmed by the demon- 
stration, (a), that the TGGGC and NF-KB binding sites could 
not cross-compete in mobility shift assays, and (b), by anti- 
body supershift experiments in which anti-p65, anti-c-tel, 
and anti-p50 antibodies that could supershift or inhibit the 
NF-KB complexes were all completely unable to affect the 
TGGGC complexes (data not shown). Furthermore, whereas 
TNF-ol could "rescue" NF-KB binding activity in cells stimu- 
lated in the presence of forskolin, there was no rescue of the 
TGGGC factor (data not shown). These results, and data 
presented below, show that the regulation of activation of 
these two binding activities was different. 
The presence of forskolin during stimulation appeared to 
result in a reduction in the total amount of NF-KB complexes 
per cell, not simply a sequestration f NF-KB activity (26). 
This was shown both by Western blotting of nuclear and 
cytoplasmic extracts with antibodies against p65, p50, and 
c-rel, and by using deoxycholate to dissociate NF-KB/IKB com- 
plexes, thus revealing previously masked NF-KB binding ac- 
tivities (27). Stimulation for 4 h led to a sharp increase of 
p65/p50 and c-rel/p50 complexes in the nucleus, and this 
increase was profoundly antagonized by the presence of for- 
skolin. However, there was no compensatory increase in NF-KB 
components orbinding activities in the cytoplasm (data not 
shown). Thus, forskolin may inhibit NF-gB synthesis or pro- 
mote NF-KB degradation. 
Delayed Inhibition of lL-2 Expression Via Delayed Inhibition 
of NF-KR The effects of forskolin on NF-KB appear to be 
paradoxical, for it has been reported that PKA can activate 
NF-gB, and our own earlier study (20) did not show consis- 
tent reduction of NF-KB binding at 2 h of forskolin treat- 
ment. To clarify this contradiction, we did kinetic studies 
to see whether the reduction we observed here is an early 
event or a possible secondary effect. First, we examined the 
kinetics of cAMP elevation after forskolin treatment. A
significant increase in cAMP levels could be seen 15 minutes 
after administration f forskolin, reaching a maximum within 
an hour. High levels of cAMP were then retained for up 
to 6 h of forskolin treatment (Fig. 2 A). The addition of 
TPA+A23187 did not affect he initial elevation or the later 
accumulation of cAMP (Fig. 2 B). Pretreatment of cells for 
2 h with TPA+A23187 before addition of forskolin also did 
not significantly affect he subsequent elevation of cAMP (Fig. 
2 C). The high levels of cAMP sustained for many hours made 
it possible that cAMP-dependent mechanisms could exert 
effects at late time points, not just immediately after stimu- 
lation. 
In fact, the effects of forskolin on NF-KB and TGGGC 
binding factor induction showed strikingly different ime 
courses. When cells were activated in the presence of for- 
skolin, mobilization of the factors binding to the TGGGC 
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Figure 2. Sustained levation fcAMP as a func- 
tion of duration of forskolin treatment. The figure 
shows cAMP levels in EL4 cells that were cultured 
in the presence offorskolin alone (solid and dotted 
curve, A; solid curve, Band C); with TPA+A23187+ 
forskolin added simultaneously (dots, B); or with 
forskolin added (time 0) after 2h of pretreatment 
with TPA+A23187 (dots, C). Levels of cAMP are 
also shown for IIA4 transfectants (see Fig. 4) that 
were cultured with forskolin alone (triangles, A). 
The incubation was stopped atdifferent time points 
and cAMP was measured in aliquots of 10 s cells. 
As a reference for the data in A-C, the data from 
EL4 cells treated with forskolin alone (A) were used 
to calculate he solid curve shown in all three panels. Individual data points were plotted as triangles or dots to compare with the solid curve. This 
comparison emphasizes the similarity in the kinetics of cAMP accumulations with or without stimulation. The experimental d ta for forskolin-treated 
EL4 cells (solid cuwe) are well-represented by the equation C(, ) = Ks/Kd - (Ks/Ka - C0)exp(-Kat), where C(0 is the amount (fmol) of cAMP/106 
cells at time t (h). Co (=568 fmol/106 cells) is the amount of cAMP at time 0, Ks (=1.6 x 104 fmol/106 cells h) is the calculated cAMP synthesis 
rate constant in the presence offorskolin. Ka (=1.14 h-1) is the cAMP decay rate constant, from which we compute l/2 = 0.79 h. 
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Figure 3. Delayed inhibition of IL-2 RNA accumulation 
correlated with delayed inhibition of NF-KB binding activity. 
(A) NF-KB and TGGGC site binding activities were m asured 
at different intervals of timulation (~) ,  in the presence 
(F-I), or absence of forskolin, as indicated in the bar graph 
over each lane. Note that it took 4 h of forskolin treatment 
to reduce NF-KB binding activity, whether forskolin addi- 
tion was delayed or not (lanes 6 and 7), but only 2 h to reduce 
TGGGC binding activity significantly (lanes 10 and11). (B) 
IL-2 mRNA levels at various times of timulation were mea- 
sured by RNase protection analysis. Data were collected from 
two independent experiments. (Left)Cells stimulated for the 
indicated lengths of time in the absence ([/]) or presence (  9  
of forskolin from time 0. (Right) Forskolin and CsA chase 
experiments. All samples were stimulated from time 0. For- 
skolin (O) or CsA (D) was added to the culture 2 h after 
initiating the stimulation with TPA+A23187. 
site was inhibited both at 2 and at 4 h of treatment (Fig. 
3 A, compare lanes 9 and 11, 12, and 14), indicating that 
this inhibition is an early event. However, when analyzed 
after 2 h of stimulation, NF-KB binding activities appeared 
to be induced equally well whether forskolin was present or 
not (Fig. 3 A, compare lanes 2 and 4). Only after at least 
4 h of stimulation in the presence of forskolin did we see 
the characteristic decrease of the NF-KB site binding activity 
(Fig. 3 A, compare lanes 5 and 7). These findings indicated 
that elevation of cAMP does not inhibit the initial dissocia- 
tion of NF-rB from IKB or its subsequent nuclear localiza- 
935 Chen and Rothenberg 
tion. They also suggested either that the effects of forskolin 
on NF-KB were intrinsically subject o delay, or that NF-KB 
proteins only became susceptible to forskolin-dependent i -
hibition at some point at least 2 h after initial exposure to 
TPA+A23187. To test these possibilities, we first stimulated 
the cells with TPA and A23187 for 2 h, to make all the neces- 
sary trans-acting factors available and initiate transcription of 
IL-2 RNA,  then we introduced 10/zM forskolin to the cul- 
ture and continued the culture for another 2 or 4 h. As shown 
in Fig. 3 A (lanes 3 and 6), forskolin "chasing" for 2 h still 
had little effect on NF-KB binding, but chasing for 4 h greatly 
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reduced the binding. These results uggested that PKA acti- 
vation had an intrinsically delayed effect on NF-KB binding 
activity. 
The delayed and asynchronous effects of cAMP elevation 
on the NF-KB and TGGGC site binding factors were associated 
with delayed inhibition of IL-2 mRNA expression, as shown 
in Fig. 3 B. IL-2 mR.NA accumulation in the stimulated con- 
trol cells followed biphasic kinetics with a relatively low rate 
of accumulation in the first 2 h, which then shifted to a higher 
rate that was sustained for the next 4 h. When forskolin was 
present at the start of stimulation, IL-2 mRNA initially ac- 
cumulated almost as fast as in the control cells without for- 
skolin, but then declined to baseline between 2 and 4 h of 
stimulation (Fig. 3 B, left). When the addition of forskolin 
was delayed until after 2 h of stimulation, the rate of IL-2 
mRNA accumulation was significantly reduced as compared 
with the control samples without forskolin, and inhibitory 
effects were evident within the first 2 h of forskolin chasing 
(Fig. 3 B, right). However, this inhibition was slow as com- 
pared with the immediate shut-off of IL-2 mRNA accumu- 
lation when CsA, instead of forskolin, was added after 2 h 
of stimulation (Fig. 3 B, right). Thus, some early effects of 
forskolin which inhibit IL-2 activation may be exerted be- 
fore its effects on NF-~cB, suggesting that a lack of factors 
other than NF-KB, including the TGGGC binding factor, 
may be sufficient to hinder the transcription but not o block 
it fully. The reduced NF-KB binding activity seen at rela- 
tively later time points would then be associated with the 
complete arrest of IL-2 mR.NA accumulation. 
Effects of Forskolin Are Mediated by PKA. Forskolin ele- 
vates intracellular cAMP by directly activating adenylate ey- 
clase, and cAMP in turn activates cAMP-dependent protein 
kinases (PKA). To ascertain whether all the effects of for- 
skolin depend on the activation of PKA, we introduced a 
dominant negative mutant PKA regulatory subunit cDNA 
construct, driven by the Harvey sarcoma virus LTR, into EL4 
cells (28). The product encoded by this construct has two 
point mutations atcAMP-binding sites which block its binding 
to cAMP but still allow it to associate with the catalytic 
subunits in competition with endogenous regulatory subunits. 
Once bound, the mutant regulatory subunit will not dis- 
sociate from the catalytic subunit in response to cAMP and 
therefore acts as a dominant negative regulator of PKA ac- 
tivity. One stable transfectant line showing high expression 
of the mutant subunit, IIA4, and two pSV2neo transfectant 
control lines, were tested to compare their forskolin responses. 
As shown in Fig. 2 A (triangles), the introduction of the mu- 
tant subunit had no effect on the ability of the cells to elevate 
their cAMP levels in response to forskolin. However, the mu- 
tant subunit completely protected the induction of IL-2 
mRNA from forskolin inhibition in the IIA4 line, in con- 
trast to the significant inhibition of IL-2 expression by for- 
skolin in control lines as measured 4 h after stimulation (Fig. 
4 A). In agreement with its effects on IL-2 mRNA expres- 
sion, expression of the dominant negative mutant PKA also 
relieved the inhibitory effects of forskolin on NF-KB and 
TGGGC binding activity (Fig. 4 B). The NF-KB and TGGGC 
Figure 4. Dominant egative mutant PKA transfected cells are resis- 
tant o the forskolin i hibitory effect. (A) Levels of II.-2 mRNA induced 
in two control lines of pSV2neo transfectants, IB2 and IB6, and in one 
line of mutant PKA transfectants, IIA4, were compared byRNase protec- 
tion analysis with 10 #g of RNA from uninduced cells (-), or cells after 
4-h stimulations (+) in the absence orpresence (F) of forskolin. 1 #g of 
RNA from each sample was hybridized with actin probe to verify com- 
parability and integrity ofthe R.NA. (B) Nuclear extracts from IIA4 cells 
were tested for NF-KB and TGGGC binding activities. All stimulations 
were for 4 h. (-) Uninduced; (+) induced with TPA and A23187; (F) 
induced with TPA and A23187 in the presence offorskolin; (/) induced 
with TPA and A23187 in the presence of50 U/ml IL-1. 
binding complexes, and the two lower inducible CACCC 
binding complexes, were fully inducible in the mutant PKA- 
containing cell line IIA4 whether forskolin was added or not 
(compare Figs. 4 B and 1 B; and data not shown). The binding 
activities of other factors in forskolin-treated IIA4 cells re- 
mained the same as in cells stimulated without forskolin (data 
not shown). The mutant cells were not simply refractory to 
modulation of NF-t~B activity, for they remained capable of 
upregulating their NF-KB site binding activity upon stimu- 
lation in the presence of 50 U/ml IL-1 (Fig. 4 B, lane 4) 
(20). Therefore, it is clear that PKA is a mediator of the in- 
hibitory effects of forskolin on DNA-binding activities. 
Forskolin Inhibits Stable In Vivo Assembly of the IL-2 DNA- 
Protein Complex. The highly selective effects of forskolin on 
particular DNA-binding activities raised the question of 
whether the binding activities that remain are capable of 
forming stable contacts with IL-2 regulatory DNA in the 
nuclei of forskolin-treated, stimulated cells. To resolve this 
issue, living cells were treated with dimethyl sulfate (DMS), 
which methylates G residues (met-G) in the major groove. 
936 cAMP Inhibits Binding of NF-xB and a Novel Factor to the IL-2 Enhancer 
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Intimate protein contacts with these residues can either pro- 
tect them from methylation or make them hypersensitive to
methylation. The subsequent piperidine cleavage of the ex- 
tracted DNA at met-Gs followed by ligation-mediated PCR 
amplification generates a G-specific sequence ladder. In fact, 
this technique has revealed specific major groove contacts at 
most or all of the sites known to be required for IL-2 expres- 
sion (19). In agreement with the results we have shown pre- 
viously (19), there is no obvious difference in the G ladder 
pattern between the DNA from DMS-treated, uninduced cells 
and naked control DNA which was DMS treated after 
purification (Fig. 5 A, lanes 1, 2, and 5). However, multiple 
footprints panning almost the entire 300-bp upstream se- 
quence were found in DNA from cells stimulated for 4 h 
with TPA+A23187 in the absence of forskolin, which cor- 
responded to the well-characterized c/selements noted previ- 
ously (Fig. 5, compare lanes 2 and 3 in A and lanes 1 and 
2 in B). Whereas these DMS footprinting results do not rule 
out some form of protein-DNA associations at the IL-2 locus 
in uninduced cells, such associations clearly do not include 
the diagnostic, specific contacts that are formed at regula- 
tory sites in induced cells. As noted above, these specific sites 
of occupancy define the oligonucleotide probes used in Fig. 
1. Each site was revealed in vivo by protection (O~) ,  hyper- 
sensitivity ( ~ ), or a characteristic pattern of both; ex- 
amples are shown in Fig. 5 C. As previously discussed (19), 
G residues in the footprint are never completely protected 
from cleavage, and this effect is exacerbated bythe asynchrony 
of IL-2 transcription i the stimulated population, in contrast 
with the more complete protection seen in the regulatory 
sequence of a constitutively expressed gene such as metal- 
lothionein-I (19, and data not shown). However, the pattern 
of protections and hypersensitivities at the IL-2 locus in stimu- 
lated cells was still highly reproducible. 
When examining the DNA from cells induced for 4 h in 
the presence of forskolin, pronounced ifferences from the 
characteristic nduced pattern were noted. First, at almost 
every cis element, signs of occupancy were absent (Fig. 5, 
A, lane 4 and B, lane 3). Not only were the NF-KB and 
TGGGC sites empty, but the two NF-AT sites (Fig. 5 C), 
the AP-1 site and the proximal CACCC site also remained 
unoccupied, even though the factors binding these latter sites 
were present in the nucleus and were able to bind to their 
sites individually as shown by in vitro mobility shift studies 
(see above, Fig. 1). The global blockade of stable footprint 
formation is reminiscent of the CsA effect, which tightly 
shuts off IL-2 transcription and completely eliminates all evi- 
dence for protein-DNA interaction in footprinting analysis 
(19 and see below). Only one sign of protein-DNA interac- 
tion was consistently seen in the cells stimulated in the pres- 
ence of forskolin: a persistent hypersensitivity at the 5'-most 
G in the distal CACCC element. The significance of this 
isolated feature, at the border of the known IL-2 enhancer, 
is unknown. 
The elimination of protein-DNA contacts in cells that had 
been stimulated in the presence of forskolin was dependent 
on PKA activity, as shown with DNA samples from mutant 
PKA transfectants. Like the parental cells, IIA4 cells estab- 
lished a full range of protein-DNA contacts in response to 
TPA+A23187 (Fig. 5, A, lane 6; B, lane 5). In contrast o 
the wild-type parental EL4 cells, treatment of IIA4 cells with 
forskolin did not affect any of the TPA+A23187-induced pro- 
tections and hypersensitivities on the DNA sequence ladder 
(Fig. 5, compare lanes 4 and 7 in A and lanes 3 and 6 in 
B). Thus the disruption of protein-DNA contacts at the IL-2 
locus was a specific effect of PKA activation. 
The effect of cAMP elevation on protein-DNA contacts 
differed from that of CsA, described previously (19), in that 
the initial establishment of footprints proceeded normally in 
the presence of TPA+A23187 +forskolin, for example as mea- 
sured after 2 h of stimulation (data not shown). The absence 
of footprints at the later time points thus reflected the net 
disassembly ofpreexisting complexes. To confirm the ability 
of forskolin treatment to block continuation of occupancy, 
we examined DNA samples from two independent forskolin 
chasing experiments (Fig. 6). In agreement with the binding 
studies and RNA analysis, the results showed that 2 h of 
forskolin chasing after 2 h of stimulation did not change the 
preexisting footprints formed after 2-h stimulation (Fig. 6, 
lane 3). By contrast, the same 2-h chase with CsA completely 
reversed the stimulated footprint pattern to an "uninduced" 
one (Fig. 6, lane 4). When forskolin chasing was extended 
to 4 h, however, a gradual weakening of protein-DNA in- 
teractions was seen (Fig. 6, lane 9). Notably, footprints 
weakened at all sites concomitantly, with the unstimulated 
pattern reemerging as quickly at the NF-AT site as at the 
NF-KB site. Thus, even preformed IL-2 DNA-protein com- 
plexes are not stable in vivo in activated cells without the 
continued contribution of forskolin-sensitive components. 
Discussion 
Agonists that elevate intracellular cAMP are likely modu- 
lators of immune responses in vivo (6-10). We and others 
have previously shown that they selectively interfere with IL-2 
expression. Here we also report hat the inhibition can follow 
a distinctively delayed time course, allowing an initial limited 
burst of IL-2 expression before transcription ceases. These 
qualitative and kinetic effects on cytokine gene expression 
resulting from the elevation of cAMP could be used in vivo 
to play a role in the shaping of a Th2 vs. Thl response. 
In this work, we present molecular evidence for the way 
elevation of cAMP downregulates xpression of the IL-2 gene 
in a model cell line. At least wo transcription factors associated 
with IL-2 activation, including NF-KB and the newly de- 
scribed TGGGC-binding factor, were specifically reduced in 
nuclear extracts from cells that were activated in the presence 
of forskolin. This pattern of transcription factor inhibition 
differed markedly from the patterns of inhibition by CsA treat- 
ment or anergy induction, in that neither NF-AT nor AP-1 
binding activities were detectably reduced. With a closer look 
at protein-DNA interactions by in vivo footprinting, we dis- 
covered that the loss of the NF-KB and TGGGC binding ac- 
tivities was correlated with the disappearance of stable pro- 
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tein-DNA contacts at virtually all detectable sites in the IL-2 
enhancer. Thus, cAMP-sensitive transcription factors appear 
to be as necessary as the CsA-sensitive factors described pre- 
viously (19) for the maintenance of transcription factor com- 
plexes at the IL-2 locus. 
Mechanism of Forskolin Effects on NF-rB. All the inhibi- 
tory effects of forskolin treatment studied here were executed 
by cAMP-dependent protein kinases, since cells expressing 
a dominant negative PKA mutant were completely resistant 
to forskolin effects. These cells preserved a high level of IL-2 
mRNA accumulation, full NF-KB and TGGGC binding ac- 
tivities in their nuclear extracts, and persistent high affinity 
protein-DNA interactions at the IL-2 locus even in the pres- 
ence of forskolin. In some cellular contexts, NF-KB can be 
activated by PKA (26, 29-31), but in stimulated EL4 cells, 
the net role of PKA is to inhibit NF-KB availability. Because 
it was not a complete failure of NF-rB induction but rather 
an inability to sustain NF-KB activation that was observed, 
it remains possible that early PKA activation might initially 
synergize with PKC to activate NF-KB through immediate 
IrB phosphorylation (27, 29-31). However, recent work has 
described additional pathways for PKA that provide a basis 
for delayed effects. It was reported that it takes 30 min for 
the catalytic subunit of PKA to translocate to the nucleus, 
and phosphorylation f the cAMP response factor CREB and 
CREB-dependent gene activation occur only afterwards (32). 
Thus a delayed effect of cAMP elevation on NF-rB levels would 
be expected if the inhibition were dependent on de novo tran- 
scription of some target gene. Preliminary experiments did 
not reveal qualitative differences between the types of NF- 
rB/c-Rel complexes induced at 2 h, at 4 h, and at 2 h in 
the presence of forskolin (data not shown). However, any 
sustained NF-rB activation, as observed in stimulated EL4 
cells, requires both new synthesis and ongoing nuclear trans- 
location of NF-rB molecules (33). Forskolin could interfere 
with this by (a) causing direct cAMP-dependent repression 
of ongoing NF-rB subunit ranscription; (b) causing cAMP- 
dependent overexpression f an appropriate form of IrB; or 
(c) directly or indirectly stimulating NF-KB proteolysis. The 
degree to which each of these mechanisms contributes to the 
lagged inhibition of NF-rB binding activity remains to be 
determined. 
How Are Reduced NF-rB and TGGGC Binding Activities 
Related to the Inhibition of IL-2 Gene Expression? In our 
938 cAMP Inhibits Binding ofNF-rB and a Novel Factor to the IL-2 Enhancer 
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Figure 5. Forskolin affects the formation f specific 
DNA binding complexes at multiple sites of the 
IL-2 promoter/enhancer region. In vivo genomic foot- 
printing on IL-2 300-bp promoter/enhancer regions 
was performed with DNA samples from EL4 (lanes 
2-4, A and lanes I-3, B) and IIA4 cells (lanes 5-7, 
A and lanes 4-6, B) cultured under different condi- 
tions. Resulting ladders for the coding strand are shown 
in A, and for the noncoding strand in B. (C)A close 
view of the effects of forskolin treatment on footprints 
at the distal nd proximal NF-AT sites. (A and B) 
Specific sites and the distance r lative to the transcrip- 
tion start site ar  as indicated. (N) Naked DNA sample 
from EL4 cells; ( - ) unstimulated cells; (+) induced 
with TPA+A23187 for 4 h; (F) induced with 
TPA+A23187 + forskolin for 4 h. Comparing lanes be- 
tween the uninduced and induced samples, multiple 
footprints throughout the whole 300-bp region are 
dearly observed, consisting ofreproducible partial pro- 
tections (O1~) and hypersensitivities ( .-~ ). In the 
forskolin-treated EL4 lane, the sequence hdder gener- 
ally resembles the uninduced one, with the exception 
of the hypersensitive G in the distal CACCC site (non- 
sense strand), as noted in the text. However, as s en 
in lanes 5-7 for both strands, forskolin did not affect 
the footprint formation in IIA4 cells.This subline x- 
hibited relatively weak footprints in general, but there 
was no significant difference b tween the footprints 
in induced samples of the mutant cells whether for- 
skolin was present or not. 
previous tudies (19), we described three extreme situations: 
when the IL-2 gene was silent, fully activated, or suppressed 
by CsA. Each condition was associated with the availability 
of a different spectrum of IL-2 DNA binding proteins as as- 
sayed in nuclear extracts. However, in vivo footprints revealed 
a simpler dichotomy, with either no detectable occupancy 
or a fully occupied footprinting pattern (Fig. 7). This indi- 
cated that in vivo, transcription factors interact with IL-2 
regulatory DNA in a highly coordinated, all-or-none fashion. 
The effects of forskolin treatment on in vivo footprints at 
the IL-2 locus enhance the previous conclusion in three ways. 
First, the key finding is that exposure to forskolin during 
stimulation blocks the formation of stable footprints at vir- 
tually all the sites of protein-DNA contact hat we detect 
in the IL-2 enhancer. In nuclear extracts from forskolin-treated 
cells, almost all the major binding activities for these sites 
appeared to be available at normal evels; only two major corn- 
939 Chen and Rothenberg 
plexes, the upper NF-~B and TGGGC complexes, were 
affected. Yet in the nuclei of living, forskolin-treated cells, 
none of the binding activities could in fact engage their target 
sites in the context of the full IL-2 enhancer (Fig. 7). In vivo, 
the binding of forskolin-insensitive factors like NF-AT was 
therefore contingent upon the binding of forskolin-sensitive 
factors like NF-~B. This finding parallels the effect of CsA 
on the establishment of stable contacts (19, and Fig. 6). How- 
ever, as summarized in Fig. 7, a different subset of factors 
is prominently affected by each inhibitor. The effect of CsA 
treatment, considered alone, made it possible to speculate that 
a single CsA-sensitive factor, like NF-AT, might play a unique 
role in opening the IL-2 chromatin structure for transcrip- 
tion. However, considered in light of the similar effects of 
forskolin treatment, such a model is much less likely. A prob- 
able inference from the results summarized in Fig. 7 is that 
the assembly of stable transcription factor complexes at the 
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Figure 6. Forskolin has delayed effects on the stability of preformed 
protein-DNA complexes. In vivo footprints at three regions of the IL-2 
regulatory sequence (sense strand) are shown. The data in lanes 1-4 and 
in lanes 5-9 are from two independent experiments. La es1and 5 contain 
DNA from uninduced cells. Lanes 2 and 6 contain DNA from cells in- 
duced with TPA+A23187 for 2 h. In lanes 3 and 4, cells were stimulated 
for 2 h, and then forskolin (lane 3) or CsA (lane 4) were added for another 
2 h. In lane 3, the inducible footprints seen in lane 2 remain id ntifiable. 
However, in lane 4, those inducible footprints see  in lanes 2and 3 disap- 
pear and the overall sequence ladder approaches the uninduced state seen 
in lane 1. In lane 7, cells were stimulated for 4 h without inhibitor. In 
lane 8, cells were stimulated for 4 h with forskolin added from time 0. 
In lane 9, cells were prestimulated for 2 h, then incubated with forskolin 
for another 4 h. Stimulated s mples without inhibitors (lanes 2, 6, and 
7) are indicated with asterisks. 
IL-2 locus requires muhivalent protein-protein teractions 
as well as the protein-DNA interactions at the individual 
sites. Thus, a major component of the combinatorial ction 
of these transcription factors may be the cooperativity required 
for their binding. 
Second, a further clue to support he need for cooperative 
binding in IL-2 regulation may be provided by the persis- 
tence of a sole residual site of activation-associated pro- 
tein-DNA contact in nuclei of forskolin-treated cells, long 
after other footprints have disappeared. The transcription factor 
or nucleosomal structure responsible for this feature is un- 
known. The isolated DMS hypersensitivity at the distal 
CACCC site is a structure that is not only distinguished from 
the resting state and the fully activated state of the IL-2 locus, 
but also distinguished from the state of the IL-2 locus in cells 
activated in the presence of CsA. The equivalence of the CsA- 
treated pattern with the resting (uninduced) pattern had not 
allowed us to distinguish whether limited chromatin accessi- 
bility or a requirement for cooperative binding actually re- 
stricted occupancy. However, it is less likely that "accessi- 
bility" is limiting after PKA activation, since residual CACCC 
occupancy is still permitted in forskolin-treated cells. 
Finally, the effect of forskolin differs from that of CsA (19) 
in that the presence of forskolin does not block transcription 
factor binding initially. In fact, the time course of its effect 
on in vivo protein-DNA contacts is delayed in parallel with 
the effect on NF-KB availability. This indicates that a key role 
is played by NF-KB or by a factor(s) inhibited with a similar 
time course. The transient assembly and disassembly of com- 
plexes in forskolin-treated cells suggests that "stable" com- 
plex formation could be a misnomer in general. Instead, the 
accessibility of the IL-2 gene to sharply discontinuous regu- 
lation may result from rapid cycling of transcription factors 
between disassembled and reassembled states. The rate of tran- 
scriptional initiation, by this model, would depend on the 
rate with which the most limiting component could be n- 
gaged. Such a model would explain how forskolin could first 
inhibit IL-2 expression to a modest degree, through reduc- 
tion in the TGGGC factor, and then more severely as NF-KB 
complexes also became rare. Further support for this interpre- 
tation is provided by the results of the experiments in which 
cells were stimulated normally, then subjected to a inhibitor 
chase. Forskolin and CsA work through completely different 
mechanisms, resulting in blocking the availability of different 
subsets of factors, yet both can shift the equilibrium to dis- 
sociation of active IL-2 transcription complexes. 
This study adds a third set of transcription factors to those 
already known to be critical for physiological regulation of 
IL-2. As discussed in the introduction, inhibition of NF-AT 
and inhibition of AP-1 separately can block IL-2 expression. 
Neither of these factors is detectably inhibited by forskolin. 
Our results suggest a similar need for NF-KB, the TGGGC 
factors, and/or other factors that are sensitive to PKA activa- 
tion. In vivo footprinting data are not yet available for any 
of the cases where AP-1 is selectively inhibited. However, 
generalizing from the effects of forskolin and the effects of 
CsA, we could predict hat selective AP-1 inactivation would 
also destabilize the whole protein-DNA assembly at the IL-2 
enhancer. This would confirm a nonhierarchical requirement 
for the various IL-2 regulatory factors. Such a mechanism 
vividly illustrates how, as a cell-specific and activation- 
dependent response, IL-2 expression is rendered vulnerable 
to multiple signaling events. 
Figure 7. Summary ofthe availability and in vivo binding 
to the IL-2 enhancer ofdifferent transcription factors, as mea- 
sured by gel mobility shift assays and in vivo footprinting 
in EL4 cells under different stimulation conditions. (Stim.) 
TPA+A23187; (+CsA) TPA+A23187+CsA; (+FKL) 
TPA+A23187 + forskolin. The pattern shown represents re ults 
obtained when stimulation, in thepresence orabsence ofthe 
indicated agents, is carried out for at least 4 h. 
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